Back

The relationship between changes of antithrombotic drug regimen after ischemic stroke and risks of clinical outcomes in patients with atrial fibrillation

25 August 2023 (09:20 - 09:30)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation and stroke: role of kidney disease and biomarkers Stroke in Atrial Fibrillation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)

3 More presentations in this session

Presentation thumbnail
Stroke, mortality, and major bleeding among patients with atrial fibrillation and chronic kidney disease; insights from a contemporary large-scale population study
Doctor Y. Ben Baruch Golan (London, GB)
Abstract Slides Video
Presentation thumbnail
Kidney function by creatinine and cystatin c and adverse cardiovascular outcomes in patients with atrial fibrillation
Mr A. Schweigler (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Neurofilament light chain (NFL) - a neuron-specific plasma biomarker for evaluating risk of ischemic cerebral events in atrial fibrillation
Doctor J. Aulin (Uppsala, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation and stroke: role of kidney disease and biomarkers
Video

The Event

Event poster

ESC Congress 2023

25 August 2023 09:20 CET
You may be interested in
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
The optimal antithrombotic strategy for post-stroke patients with atrial fibrillation and extracranial artery stenosis - A nationwide cohort study
thumbnail
Congress Session
Optimising atrial fibrillation detection and management in people after stroke

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources